News

Servier invests in oncology
Enlarge image

BusinessFrance

Servier invests in oncology

25.09.2012 - French pharma company Les Laboratoires Servier beefs up its oncology pipeline with a deal worth up to US$1.2bn.

In its second deal with US-based Macrogenics, the major French pharma company has entered into an option agreement to develop and commercialise three Macrogenics products. Under the terms of the agreement, Macrogenics receives US$20m upfront, as well as US$1.1bn in milestone payments and double digit royalties. It will use its Dual-Affinity Re-Targeting (DART) platform to develop up to three proteins that target un-diagnosed solid and liquid tumours. It retains full development and commercialisation rights to the programmes in the US, Canada, Mexico, Japan, Korea and India, while Servier has the option to obtain an exclusive license covering the rest of the world for each of the programmes.

„We believe bi-specific antibodies are an important new frontier in medicine. Macrogenics is well positioned to be a leader in this exciting area, given the robustness and versatility of their DART platform”, said Stéphane Depil, in charge of Oncology Research & Development at Servier. His company partnered with Macrogenics for the first time in late 2011 on MGA271, a monoclonal antibody that recognises B7-H3, a novel member of the B7 family of immune regulators. With Pfizer and Boehringer Ingelheim, two other major pharma companies are already using the DART platform since at least October 2010.

These deals mark a remarkable comeback for Macrogenics: only two years ago the company spiked ist lead product, type 1 diabetes drug teplizumab, partnered to Eli Lilly & Co., after disappointing Phase III study results

© eurobiotechnews.eu/bk

BusinessSwitzerlandUK

23.04.2014 In an effort to focus on key businesses, pharma giant Novartis is joining forces with long-time rival GlaxoSmithKline in a multi-billion Euro asset exchange and an OTC joint venture.

FinanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK70.9%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.1%
  • IMMUNICUM AB (S)16.60 SEK-38.1%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP750.0%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-96.0%
  • EVOCUTIS (UK)0.22 GBP-92.3%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 22.04.2014